v3.26.3
Accumulated other comprehensive income (loss)
 9 Months Ended
Sep. 30, 2026
Stockholders' Equity Note [Abstract]  
Accumulated other comprehensive income (loss) ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS):
a. Accumulated other comprehensive loss
The components of, and changes within, accumulated other comprehensive income (loss) attributable to Teva are presented in the table below:
Net Unrealized Gains (Losses)Benefit Plans
Foreign currency translation adjustmentsDerivative financial instrumentsActuarial gains (losses) and prior service (costs) creditsTotal
(U.S. $ in millions)
Balance as of December 31, 2025, net of taxes$(2,152)$(199)$(39)$(2,391)
Other comprehensive income (loss) before reclassifications(131)(35)— (167)
Amounts reclassified to the statements of income— 13 (2)11 
Release of cumulative translation adjustments(6)— — (6)
Net other comprehensive income (loss) before tax(137)(23)(2)(162)
Corresponding income tax(3)— — (3)
Net other comprehensive income (loss) after tax(140)(23)(2)(165)
Balance as of September 30, 2026, net of taxes$(2,292)$(222)$(41)$(2,556)

Net Unrealized Gains (Losses)Benefit Plans
Foreign currency translation adjustmentsDerivative financial instrumentsActuarial gains (losses) and prior service (costs) creditsTotal
(U.S. $ in millions)
Balance as of December 31, 2024, net of taxes$(2,857)$(238)$(52)$(3,148)
Other comprehensive income (loss) before reclassifications509 — — 509 
Amounts reclassified to the statements of income— 30 (2)28 
Release of cumulative translation adjustments**181 — — 181 
Net other comprehensive income (loss) before tax690 30 (2)718 
Corresponding income tax(45)— — (45)
Net other comprehensive income (loss) after tax*645 30 (2)673 
Balance as of September 30, 2025, net of taxes$(2,212)$(208)$(54)$(2,475)
__________
* Amounts do not include a $27 million gain from foreign currency translation adjustments attributable to redeemable and non-redeemable non-controlling interests.
** In connection with the sale of Teva’s business venture in Japan.
 b. Ordinary shares
As of September 30, 2026 and December 31, 2025, Teva had approximately 1.3 billion ordinary shares issued, respectively. Teva ordinary shares are traded on both the Tel Aviv Stock Exchange and the New York Stock Exchange under the symbol "TEVA".
Prior to September 14, 2026, Teva's ordinary shares traded on the New York Stock Exchange in the form of American Depositary Shares ("ADSs"), each representing one ordinary share. On September 14, 2026, Teva's ADS program was terminated and each ADS was exchanged for one ordinary share.